Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma

Journal of Neurochemistry

Volumn 134, Issue 5, 2015, Pages 811-818

  Lan, Fengming ^a   Pan, Qiang ^b   Yu, Huiming ^c   Yue, Xiao ^d  

^a TIANJIN HOSPITAL   (China)

^b Laiwu People s Hospital   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d TIANJIN HUANHU HOSPITAL   (China)

Author keywords

apoptosis; glioblastoma; miR 21; sulforaphane; temozolomide; Wnt catenin signaling

Indexed keywords

BETA CATENIN; MICRORNA 21; PROTEIN BAX; PROTEIN BCL 2; SULFORAPHANE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG; WNT PROTEIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; ISOTHIOCYANIC ACID DERIVATIVE; MICRORNA; MIRN21 MICRORNA, HUMAN; RNA; SULFORAFAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; METABOLIC INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PHYTOTHERAPY; RANDOMIZATION; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DACARBAZINE; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; ISOTHIOCYANATES; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PHYTOTHERAPY; RANDOM ALLOCATION; RNA, NEOPLASM; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938799830     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13174     Document Type: Article

References (41)

1. Barbano R., Palumbo O., Pasculli B., et al,. (2014) A MiRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS ONE 9, e108950.
2. Cornblatt B. S., Ye L., Dinkova-Kostova A. T., et al,. (2007) Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis 28, 1485-1490.
3. van Dam S., Craig T., and, de Magalhaes J. P., (2015) GeneFriends: a human RNA-seq-based gene and transcript co-expression database. Nucleic Acids Res. 43, 1124-1132.
4. Franklin S. J., Dickinson S. E., Karlage K. L., Bowden G. T., and, Myrdal P. B., (2014) Stability of sulforaphane for topical formulation. Drug Dev. Ind. Pharm. 40, 494-502.
5. Gong C., Nie Y., Qu S., et al,. (2014) miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors. Cancer Res. 74, 4341-4352.
6. Grossman R., Rudek M. A., Brastianos H., Zadnik P., Brem H., Tyler B., and, Blakeley J. O., (2012) The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother. Pharmacol. 70, 129-139.
7. Gu X., Yao L., Ma G., Cui L., Li Y., Liang W., Zhao B., and, Li K., (2014) TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced beta-catenin/TCF-4 transcription. Neuro Oncol. 16, 217-227.
8. Happold C., Roth P., Silginer M., Florea A. M., Lamszus K., Frei K., Deenen R., Reifenberger G., and, Weller M., (2014) Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol. Cancer Ther. 13, 948-961.
9. Heimberger A. B., Archer G. E., McLendon R. E., Hulette C., Friedman A. H., Friedman H. S., Bigner D. D., and, Sampson J. H., (2000) Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin. Cancer Res. 6, 4148-4153.
10. Hunakova L., Gronesova P., Horvathova E., Chalupa I., Cholujova D., Duraj J., and, Sedlak J., (2014) Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane. Toxicol. Lett. 230, 479-486.
11. Jackson S. J., and, Singletary K. W., (2004) Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis 25, 219-227.
12. Kallifatidis G., Labsch S., Rausch V., Mattern J., Gladkich J., Moldenhauer G., Buchler M. W., Salnikov A. V., and, Herr I., (2011) Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol. Ther. 19, 188-195.
13. Kaminski B. M., Weigert A., Brune B., Schumacher M., Wenzel U., Steinhilber D., Stein J., and, Ulrich S., (2011) Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemother. Pharmacol. 67, 1167-1178.
14. Kaminski B. M., Steinhilber D., Stein J. M., and, Ulrich S., (2012) Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr. Pharm. Biotechnol. 13, 137-146.
15. Karmakar S., Weinberg M. S., Banik N. L., Patel S. J., and, Ray S. K., (2006) Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141, 1265-1280.
16. Lan F., Yue X., Han L., Shi Z., Yang Y., Pu P., Yao Z., and, Kang C., (2012) Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer. Int. J. Oncol. 40, 519-526.
17. Lenzi M., Fimognari C., and, Hrelia P., (2014) Sulforaphane as a promising molecule for fighting cancer. Cancer Treat. Res. 159, 207-223.
18. Liang H., and, Yuan Q., (2012) Natural sulforaphane as a functional chemopreventive agent: including a review of isolation, purification and analysis methods. Crit. Rev. Biotechnol. 32, 218-234.
19. Lin L. C., Yeh C. T., Kuo C. C., Lee C. M., Yen G. C., Wang L. S., Wu C. H., Yang W. C., and, Wu A. T., (2012) Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/beta-catenin function. J. Agric. Food Chem. 60, 7031-7039.
20. Loftus J. C., Dhruv H., Tuncali S., et al,. (2013) TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Mol. Cancer Res. 11, 865-874.
21. Mishra S., Lin C. L., Huang T. H., Bouamar H., and, Sun L. Z., (2014) MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol. Cancer. 13, 212.
22. Myzak M. C., Karplus P. A., Chung F. L., and, Dashwood R. H., (2004) A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 64, 5767-5774.
23. Park I., Mukherjee J., Ito M., Chaumeil M. M., Jalbert L. E., Gaensler K., Ronen S. M., Nelson S. J., and, Pieper R. O., (2014) Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 74, 7115-7124.
24. Patel M. A., Kim J. E., Ruzevick J., Li G., and, Lim M., (2014) The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) 6, 1953-1985.
25. Paul I., Bhattacharya S., Chatterjee A., and, Ghosh M. K., (2013) Current understanding on EGFR and Wnt/beta-catenin signaling in glioma and their possible crosstalk. Genes Cancer 4, 427-446.
26. Pledgie-Tracy A., Sobolewski M. D., and, Davidson N. E., (2007) Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther. 6, 1013-1021.
27. Sestili P., Paolillo M., Lenzi M., Colombo E., Vallorani L., Casadei L., Martinelli C., and, Fimognari C., (2010) Sulforaphane induces DNA single strand breaks in cultured human cells. Mutat. Res. 689, 65-73.
28. Shi L., Chen J., Yang J., Pan T., Zhang S., and, Wang Z., (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res. 1352, 255-264.
29. Stedt H., Samaranayake H., Pikkarainen J., Maatta A. M., Alasaarela L., Airenne K., and, Yla-Herttuala S., (2013) Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide. Gene Ther. 20, 1165-1171.
30. Tran B., and, Rosenthal M. A., (2010) Survival comparison between glioblastoma multiforme and other incurable cancers. J. Clin. Neurosci. 17, 417-421.
31. Turrini E., Ferruzzi L., and, Fimognari C., (2014) Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues. Expert Opin. Drug Metab. Toxicol. 10, 1677-1690.
32. Vyas A. R., Hahm E. R., Arlotti J. A., Watkins S., Stolz D. B., Desai D., Amin S., and, Singh S. V., (2013) Chemoprevention of prostate cancer by d, l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res. 73, 5985-5995.
33. Wakabayashi T., Kayama T., Nishikawa R., et al,. (2011) A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. J. Neurooncol. 104, 573-577.
34. Wakimoto H., Tanaka S., Curry W. T., et al,. (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin. Cancer Res. 20, 2898-2909.
35. Wang X. F., Wu D. M., Li B. X., Lu Y. J., and, Yang B. F., (2009) Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. Phytother. Res. 23, 303-307.
36. Weller M., Gorlia T., Cairncross J. G., et al,. (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77, 1156-1164.
37. Wu Y., Zou L., Mao J., Huang J., and, Liu S., (2014) Stability and encapsulation efficiency of sulforaphane microencapsulated by spray drying. Carbohydr. Polym. 102, 497-503.
38. Yamamichi N., Shimomura R., Inada K., et al,. (2009) Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin. Cancer Res. 15, 4009-4016.
39. Yang C. H., Yue J., Pfeffer S. R., et al,. (2014) MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). J. Biol. Chem. 289, 25079-25087.
40. Yeom S. Y., Nam D. H., and, Park C., (2014) RRAD promotes EGFR-Mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma. Mol. Cancer Ther. 13, 3049-3061.
41. Yuan Y., Xue X., Guo R. B., Sun X. L., and, Hu G., (2012) Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neurosci. Ther. 18, 536-546.